SON-1210 - a novel bifunctional IL-12 / IL-15 fusion protein that improves cytokine half-life, targets tumors, and enhances therapeutic efficacy.

ABSTRACT:

Background

The potential synergy between interleukin-12 (IL-12) and IL-15 holds promise for more effective solid tumor immunotherapy. Nevertheless, previous clinical trials involving therapeutic cytokines have encountered obstacles such as short pharmacokinetics, limited tumor microenvironment (TME) targeting, and substantial systemic toxicity.

Methods

To address these challenges, we fused single-chain human IL-12 and native human IL-15 in cis onto a fully human albumin binding (F_HAB) domain single-chain antibody fragment (scFv). This novel fusion protein, IL12-F_HAB-IL15 (SON-1210), is anticipated to amplify the therapeutic impact of interleukins and combination immunotherapies in human TME. The molecule was studied in vitro and in animal

SUBMITTER: Cini JK 

PROVIDER: S-EPMC10798159 | biostudies-literature | 2023

REPOSITORIES: biostudies-literature